Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.74 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.72 |
| ▸ | TP53 | P04637 | 3/20 | 0.72 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20079684 | 0.88 | TRPA1 (0.78) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL10114054 | 0.88 | RXFP1 (0.78) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL10114044 | 0.88 | TRPA1 (0.71) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL12584246 | 0.88 | TRPA1 (0.74) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL10114140 | 0.88 | RXFP1 (0.76) | TRPA1RXFP1TP53THRBCYP1A2 | |
| SCHEMBL10113830 | 0.87 | TRPA1 (0.77) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL10114021 | 0.87 | TRPA1 (0.80) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL10130857 | 0.87 | TRPA1 (0.77) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL3826453 | 0.87 | TRPA1 (0.77) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL4533692 | 0.86 | RXFP1 (0.78) | TRPA1RXFP1TP53PORCNTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093986-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-8389529-B2 | Methods and compositions for treating asthma | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8178542-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093986-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | TRPA1 59/4885RXFP1 611/4885TP53 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.